Multimodality Risk Assessment of Patients with Ischemic Heart Disease Using Deep Learning Models Applied to Electrocardiograms and Chest X-rays.

Journal: International heart journal
Published Date:

Abstract

Comprehensive management approaches for patients with ischemic heart disease (IHD) are important aids for prognostication and treatment planning. While single-modality deep neural networks (DNNs) have shown promising performance for detecting cardiac abnormalities, the potential benefits of using DNNs for multimodality risk assessment in patients with IHD have not been reported. The purpose of this study was to investigate the effectiveness of multimodality risk assessment in patients with IHD using a DNN that utilizes 12-lead electrocardiograms (ECGs) and chest X-rays (CXRs), with the prediction of major adverse cardiovascular events (MACEs) being of particular concern.DNN models were applied to detection of left ventricular systolic dysfunction (LVSD) on ECGs and identification of cardiomegaly findings on CXRs. A total of 2107 patients who underwent elective percutaneous coronary intervention were categorized into 4 groups according to the models' outputs: Dual-modality high-risk (n = 105), ECG high-risk (n = 181), CXR high-risk (n = 392), and No-risk (n = 1,429).A total of 342 MACEs were observed. The incidence of a MACE was the highest in the Dual-modality high-risk group (P < 0.001). Multivariate Cox hazards analysis for predicting MACE revealed that the Dual-modality high-risk group had a significantly higher risk of MACE than the No-risk group (hazard ratio (HR): 2.370, P < 0.001), the ECG high-risk group (HR: 1.906, P = 0.010), and the CXR high-risk group (HR: 1.624, P = 0.018), after controlling for confounding factors.The results suggest the usefulness of multimodality risk assessment using DNN models applied to 12-lead ECG and CXR data from patients with IHD.

Authors

  • Shinnosuke Sawano
    Department of Cardiovascular Medicine, The University of Tokyo.
  • Satoshi Kodera
    Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo.
  • Masataka Sato
    Department of Cardiovascular Medicine, The University of Tokyo Hospital.
  • Hiroki Shinohara
    Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo.
  • Atsushi Kobayashi
    Department of Cardiovascular Medicine, Fukushima Medical University, Fukushima, Japan.
  • Hiroshi Takiguchi
    Department of Cardiovascular Medicine, The University of Tokyo.
  • Kazutoshi Hirose
    Department of Cardiovascular Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
  • Tatsuya Kamon
    Department of Cardiovascular Medicine, The University of Tokyo Hospital.
  • Akihito Saito
    Department of Cardiovascular Medicine, The University of Tokyo Hospital, Tokyo, Japan.
  • Hiroyuki Kiriyama
    Department of Cardiovascular Medicine, The University of Tokyo Hospital.
  • Mizuki Miura
    Department of Cardiovascular Medicine, The University of Tokyo Hospital.
  • Shun Minatsuki
    Department of Cardiovascular Medicine, The University of Tokyo Hospital, Tokyo, Japan.
  • Hironobu Kikuchi
    Department of Cardiovascular Medicine, The University of Tokyo Hospital, Tokyo, Japan.
  • Norifumi Takeda
    Department of Cardiovascular Medicine, The University of Tokyo.
  • Hiroyuki Morita
    Department of Cardiovascular Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
  • Issei Komuro
    Department of Cardiovascular Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.